CN103890587A - 用于治疗和诊断癌症的方法和组合物 - Google Patents

用于治疗和诊断癌症的方法和组合物 Download PDF

Info

Publication number
CN103890587A
CN103890587A CN201280051957.8A CN201280051957A CN103890587A CN 103890587 A CN103890587 A CN 103890587A CN 201280051957 A CN201280051957 A CN 201280051957A CN 103890587 A CN103890587 A CN 103890587A
Authority
CN
China
Prior art keywords
human
people
protein
cancer
family
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280051957.8A
Other languages
English (en)
Chinese (zh)
Inventor
克伦·查普曼
约瑟夫·瓦格纳
迈克尔·韦斯特
詹妮弗·洛丽·基德
玛丽亚·普伦德斯
马库斯·拉彻
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insight Molecular Diagnostics Inc
Original Assignee
Oncocyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncocyte Corp filed Critical Oncocyte Corp
Publication of CN103890587A publication Critical patent/CN103890587A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CN201280051957.8A 2011-08-31 2012-08-31 用于治疗和诊断癌症的方法和组合物 Pending CN103890587A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161529500P 2011-08-31 2011-08-31
US61/529,500 2011-08-31
US201161542403P 2011-10-03 2011-10-03
US61/542,403 2011-10-03
PCT/US2012/053472 WO2013033609A2 (en) 2011-08-31 2012-08-31 Methods and compositions for the treatment and diagnosis of cancer

Publications (1)

Publication Number Publication Date
CN103890587A true CN103890587A (zh) 2014-06-25

Family

ID=47757190

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280051957.8A Pending CN103890587A (zh) 2011-08-31 2012-08-31 用于治疗和诊断癌症的方法和组合物

Country Status (9)

Country Link
US (1) US20140206574A1 (enExample)
EP (1) EP2751570A4 (enExample)
JP (1) JP2014525584A (enExample)
KR (1) KR20140057361A (enExample)
CN (1) CN103890587A (enExample)
AU (1) AU2012301664A1 (enExample)
CA (1) CA2844793A1 (enExample)
HK (1) HK1199099A1 (enExample)
WO (1) WO2013033609A2 (enExample)

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105463070A (zh) * 2015-07-08 2016-04-06 上海市同仁医院 Uca1基因在制备诊断结直肠癌产品中的应用
CN105675735A (zh) * 2014-11-19 2016-06-15 上海市第六人民医院 乳腺癌诊断标记物组合、应用及其测定方法
CN106047874A (zh) * 2016-06-02 2016-10-26 吉林大学 一种靶向sall4基因的脱氧核酶分子及在乳腺癌基因治疗中的应用
WO2017113565A1 (zh) * 2015-12-29 2017-07-06 中国医学科学院肿瘤医院 基于蛋白标志物psg3辅助诊断肝癌或消化道癌症患者的试剂盒
CN107312096A (zh) * 2017-07-17 2017-11-03 武汉博欧特生物科技有限公司 用于检测组蛋白位点三甲基化修饰的重组蛋白及其应用
CN107449916A (zh) * 2017-07-27 2017-12-08 北京邦菲生物科技有限公司 肺癌和肺部结节蛋白特征谱及其构建方法与应用
CN107807243A (zh) * 2017-11-24 2018-03-16 暨南大学 一种食管癌的生物标志物及其应用
CN108138239A (zh) * 2015-07-24 2018-06-08 高丽大学校产学协力团 用于确定衰老、确定肥胖症和诊断癌症的生物标志物和使用其的诊断试剂盒
CN108152496A (zh) * 2017-11-24 2018-06-12 暨南大学 Mest蛋白在制备肺癌辅助诊断和/或预后判断的试剂盒中的应用
CN108329387A (zh) * 2017-01-17 2018-07-27 复旦大学附属肿瘤医院 癌症相关的肿瘤特异转录本lin28b-tst及其用途
CN108601811A (zh) * 2015-12-04 2018-09-28 得克萨斯州大学系统董事会 用于免疫治疗的slc45a2肽
CN108603882A (zh) * 2015-09-28 2018-09-28 雅培日本有限公司 层粘连蛋白2用于诊断肝细胞癌和胰腺癌的用途
CN108796079A (zh) * 2018-06-06 2018-11-13 天津医科大学肿瘤医院 一种逆转录转座基因l1-fggy及其作为肺鳞癌标志物的用途
WO2018218737A1 (zh) * 2017-06-01 2018-12-06 立森印迹诊断技术（无锡）有限公司 一种印记基因在膀胱肿瘤中的分级模型及其组成的系统
CN109082473A (zh) * 2018-10-16 2018-12-25 兰州大学 一种公牛znf280ay基因拷贝数变异的检测方法及应用
CN109371023A (zh) * 2018-12-11 2019-02-22 宁夏医科大学总医院 一种环状RNA hsa_circKIAA1199_006及其特异性扩增引物和应用
CN110218796A (zh) * 2019-06-27 2019-09-10 江门市中心医院 用于乳腺癌骨转移诊疗的新靶标pcdhb2
CN111218509A (zh) * 2019-12-23 2020-06-02 西南医科大学附属医院 乳腺癌的新诊断标志物ppef1及其应用
CN111479822A (zh) * 2017-12-13 2020-07-31 艾诺奥医药品有限公司 靶向lemd1的癌症疫苗和其用途
CN111954816A (zh) * 2018-03-08 2020-11-17 英美偌科有限公司 检测magea4的方法
CN112147324A (zh) * 2019-06-28 2020-12-29 欧蒙医学实验诊断股份公司 自身抗体的检测
CN112626210A (zh) * 2020-12-22 2021-04-09 上海市第一人民医院 诊断标志物gata4在胰腺“炎癌转化”中的应用
CN112639132A (zh) * 2018-05-29 2021-04-09 图尔库大学 L1td1作为结肠癌的预测生物标志物
CN113504370A (zh) * 2021-06-29 2021-10-15 广州金研生物医药研究院有限公司 Mapk15蛋白在前列腺癌的恶性程度或预后程度预测中的应用
CN114127114A (zh) * 2019-04-30 2022-03-01 目标发现联合第二附属有限责任公司 癌相关抗体组合物和使用方法
WO2023273257A1 (zh) * 2021-06-30 2023-01-05 武汉艾米森生命科技有限公司 一种结直肠癌或癌前病变的诊断或辅助诊断试剂、核酸组合、试剂盒及应用
WO2023029489A1 (zh) * 2021-09-03 2023-03-09 中山大学 一种寡核苷酸rna双链分子及其在制备治疗恶性肿瘤药物中的应用
CN115786518A (zh) * 2022-11-29 2023-03-14 广东医科大学附属医院 嗅素结构域家族蛋白4（olfm4）在结肠癌检测产品中的应用
CN115838804A (zh) * 2022-10-07 2023-03-24 厦门医学院 血浆外泌体lncRNAs作为靶标在急性髓系白血病诊断和疗效监测中的应用
CN115992229A (zh) * 2022-07-22 2023-04-21 中南大学湘雅三医院 一种胰腺癌预后风险评估的lncRNA标记物、模型及其应用
CN116087519A (zh) * 2021-05-17 2023-05-09 郑州大学第一附属医院 一种用于高危人群贲门腺癌早期筛查的标志物及其应用
CN116482365A (zh) * 2023-03-14 2023-07-25 南京芯原生物科技有限公司 用于检测血清抗体的蛋白组合物及其应用

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2626437A3 (en) 2008-05-14 2013-12-11 Dermtech International Diagnosis of melanoma and solar lentigo by nucleic acid analysis
US20150299799A1 (en) * 2012-10-05 2015-10-22 Michael Sturzl Method for Detecting an Increased Risk or Incidence of Colorectal Cancer
EP2853596A1 (en) * 2013-09-30 2015-04-01 IKBT (Institut für Klinische Biomedizinische Forschung Thurgau) Protein phosphatase inhibitor
GB201320061D0 (en) * 2013-11-13 2013-12-25 Electrophoretics Ltd Materials nad methods for diagnosis and prognosis of liver cancer
EP2876442A1 (en) * 2013-11-22 2015-05-27 Institut de Cancérologie de l'Ouest Olfactomedin-4, neudesin and desmoplakin as biomarkers of breast cancer
CA2934828A1 (en) * 2013-12-30 2015-07-09 The Henry M. Jackson Foundation For The Advancement Of Military Medici, Inc. Prostate cancer gene profiles and methods of using the same
WO2016179043A1 (en) 2015-05-01 2016-11-10 Dermtech, Inc. Non-invasive skin collection system
CA2951514C (en) * 2014-06-18 2025-09-09 Clear Gene, Inc. METHODS, COMPOSITIONS AND DEVICES FOR THE RAPID ANALYSIS OF BIOLOGICAL MARKERS
KR101779147B1 (ko) * 2014-07-04 2017-09-20 연세대학교 산학협력단 Kiaa1199를 이용한 췌장암의 진단 또는 치료용 조성물
JP6551967B2 (ja) * 2015-01-30 2019-07-31 国立大学法人山口大学 肝細胞がんの転移性再発リスクの予測方法
JP6803572B2 (ja) * 2015-03-06 2020-12-23 国立大学法人東海国立大学機構 Ｓｙｔ１３、ｓｙｔ８、ａｎｏｓ１発現量による胃癌腹膜播種の検査方法、検査キット、分子標的治療薬スクリーニング方法、及び治療薬
GB201504502D0 (en) * 2015-03-17 2015-04-29 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers
KR20240151873A (ko) 2015-03-17 2024-10-18 이매틱스 바이오테크놀로지스 게엠베하 췌장암 및 기타 암에 대한 면역요법에서의 사용을 위한 펩티드 및 펩티드의 조합
JP2016214239A (ja) * 2015-05-15 2016-12-22 国立大学法人高知大学 膵がんマーカー
JP6659250B2 (ja) * 2015-06-19 2020-03-04 国立大学法人滋賀医科大学 癌の検査方法、癌細胞増殖阻害剤、抗癌剤及び抗癌剤のスクリーニング方法
EP3327137B1 (en) * 2015-07-22 2020-12-09 National University Corporation Tottori University Host regulation factor for enhancing proliferation and propagation of vaccinia virus
CN105504060B (zh) * 2015-12-31 2018-10-26 陆梅生 一种抗胃癌细胞表面功能性表达的足萼样蛋白前体亚型2的单克隆抗体及其制备方法和用途
US10294297B2 (en) 2016-01-29 2019-05-21 The Board Of Trustees Of The Leland Stanford Junior University Methods for treatment using anti-NMU agents
CN106399306B (zh) * 2016-04-12 2019-11-05 西安交通大学第一附属医院 靶向人lncRNA-UCA1抑制膀胱癌的sgRNA、基因载体及其应用
SE540173C2 (en) * 2016-04-20 2018-04-24 Hiloprobe Ab Marker genes for colorectal cancer classification, method for judging lymph node metastasis for prognosis of colorectal cancer and kit therefor
EP3468546A4 (en) 2016-06-09 2020-04-01 Cedars-Sinai Medical Center COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
EP3625357A4 (en) * 2017-05-16 2021-02-24 The Chinese University Of Hong Kong INTEGRATIVE ANALYSIS OF ACELLULAR AND MONOCELLULAR PLASMA RNA
EP3752645A4 (en) 2018-02-14 2022-04-13 Dermtech, Inc. Novel gene classifiers and uses thereof in non-melanoma skin cancers
CN109116023B (zh) * 2018-06-14 2021-06-04 郑州大学第一附属医院 一种肺癌标志物抗-mmp12自身抗体及其应用
WO2019241899A1 (es) * 2018-06-20 2019-12-26 Pontificia Universidad Catolica De Chile Detección no invasiva de cáncer gástrico a través de la detección en sangre de la metilación de reprimo like
WO2020017676A1 (ko) * 2018-07-20 2020-01-23 주식회사 셀투인 Fresh-트레이서 기반 분리된 세포의 유전자 프로파일의 응용
KR102377702B1 (ko) 2018-10-19 2022-03-24 한국생명공학연구원 Syt11 억제제를 유효성분으로 포함하는 위암 치료용 조성물
JP7216995B2 (ja) * 2018-12-05 2023-02-02 学校法人関西医科大学 胸腺癌バイオマーカー及び胸腺腫瘍の予後予測マーカー
JP2022524641A (ja) 2019-03-26 2022-05-09 ダームテック，インク． 皮膚癌における新規な遺伝子分類子とその使用
WO2021003246A1 (en) * 2019-07-01 2021-01-07 Accure Health Inc. Predictive liquid markers for cancer immunotherapy
CN110796625B (zh) * 2019-10-30 2023-06-20 重庆邮电大学 一种基于组稀疏表示和加权全变分的图像压缩感知重构方法
US20230348592A1 (en) * 2020-05-12 2023-11-02 Memorial Sloan Kettering Cancer Center Methods for de-cloaking cancer from the immune system through downregulation of cancer-produced pregnancy specific glycoprotein
CN115216542A (zh) * 2021-04-15 2022-10-21 复旦大学附属华山医院 一组肿瘤筛查、鉴别的标志物及应用
CN114807369A (zh) * 2021-11-15 2022-07-29 四川大学华西医院 一种与前列腺癌显著相关的潜在抗原、免疫分型及其构建方法和应用
CN117487000B (zh) * 2022-08-30 2025-03-25 暨南大学 一种肿瘤T细胞抗原表位肽、pMHC及其制备和应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1481255A (zh) * 2000-10-18 2004-03-10 ʷ 疫苗
CN101194027A (zh) * 2005-06-08 2008-06-04 日立化成研究中心公司 用于基于瘤细胞及受刺激的白细胞内mRNA表达谱而预测对肿瘤疾病的免疫应答的方法
WO2009052573A1 (en) * 2007-10-23 2009-04-30 Clinical Genomics Pty. Ltd. A method of diagnosing neoplasms
WO2010104662A1 (en) * 2009-03-09 2010-09-16 University Of Georgia Research Foundation, Inc. Protein markers identification for gastric cancer diagnosis
WO2011019648A1 (en) * 2009-08-10 2011-02-17 Epitherix, Llc Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
CN102027373A (zh) * 2008-05-14 2011-04-20 埃斯苏黎世公司 发现用于前列腺癌诊断和治疗之生物标志物和药物靶标的方法及其确立的生物标志物测定
CN102089428A (zh) * 2008-05-21 2011-06-08 东丽株式会社 食道癌确定用组合物及方法
US20110206702A1 (en) * 2010-02-23 2011-08-25 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002322280A1 (en) * 2001-06-21 2003-01-21 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
US20030165954A1 (en) * 2002-01-09 2003-09-04 Third Wave Technologies, Inc. Cancer profiles
US20060188889A1 (en) * 2003-11-04 2006-08-24 Christopher Burgess Use of differentially expressed nucleic acid sequences as biomarkers for cancer
DK3170906T3 (en) * 2003-06-24 2018-11-05 Genomic Health Inc PREDICTION OF THE LIKELI REVENUE OF CANCER
US20050208499A1 (en) * 2004-02-04 2005-09-22 Graff Jonathan M Markers for diagnosing and treating breast and ovarian cancer
AU2005271113B2 (en) * 2004-08-10 2010-12-09 Cardiff Biologicals Limited Methods and kit for the prognosis of breast cancer
US20070218512A1 (en) * 2006-02-28 2007-09-20 Alex Strongin Methods related to mmp26 status as a diagnostic and prognostic tool in cancer management
DE102006024416A1 (de) * 2006-05-24 2008-04-30 Friedrich-Alexander-Universität Erlangen-Nürnberg Prädiktives Genexpressionsmuster für kolorektale Karzinome
WO2007147265A1 (en) * 2006-06-23 2007-12-27 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
EP2094719A4 (en) * 2006-12-19 2010-01-06 Genego Inc NEW PROCEDURES FOR THE FUNCTIONAL ANALYSIS OF EXPERIMENTAL HIGH-PERFORMANCE DATA AND IDENTIFIED GENDER GROUPS THEREOF
AT504702A1 (de) * 2006-12-22 2008-07-15 Arc Austrian Res Centers Gmbh Set von tumormarkern
WO2008089577A1 (en) * 2007-01-26 2008-07-31 Vm Institute Of Resaerch Breast cancer gene array
EP2048242A1 (de) * 2007-10-08 2009-04-15 Max-Delbrück-Centrum für Molekulare Medizin (MDC) Microarray für die Expressionsanalyse der zellulären Glykosylierungsmaschinerie
ES2469802T3 (es) * 2008-10-20 2014-06-20 Valipharma Métodos y usos que implican aberraciones genéticas de NAV 3 y expresión aberrante de múltiples genes
CA3153682A1 (en) * 2008-11-17 2010-05-20 Veracyte, Inc. Methods and compositions of molecular profiling for disease diagnostics

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1481255A (zh) * 2000-10-18 2004-03-10 ʷ 疫苗
CN101194027A (zh) * 2005-06-08 2008-06-04 日立化成研究中心公司 用于基于瘤细胞及受刺激的白细胞内mRNA表达谱而预测对肿瘤疾病的免疫应答的方法
WO2009052573A1 (en) * 2007-10-23 2009-04-30 Clinical Genomics Pty. Ltd. A method of diagnosing neoplasms
CN102027373A (zh) * 2008-05-14 2011-04-20 埃斯苏黎世公司 发现用于前列腺癌诊断和治疗之生物标志物和药物靶标的方法及其确立的生物标志物测定
CN102089428A (zh) * 2008-05-21 2011-06-08 东丽株式会社 食道癌确定用组合物及方法
WO2010104662A1 (en) * 2009-03-09 2010-09-16 University Of Georgia Research Foundation, Inc. Protein markers identification for gastric cancer diagnosis
WO2011019648A1 (en) * 2009-08-10 2011-02-17 Epitherix, Llc Indazoles as wnt/b-catenin signaling pathway inhibitors and therapeutic uses thereof
US20110206702A1 (en) * 2010-02-23 2011-08-25 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CAROLINE BRET ET AL.: "Expression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cells", 《BRITISH JOURNAL OF HAEMATOLOGY》 *

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105675735B (zh) * 2014-11-19 2018-07-17 上海市第六人民医院 乳腺癌诊断标记物组合、应用及其测定方法
CN105675735A (zh) * 2014-11-19 2016-06-15 上海市第六人民医院 乳腺癌诊断标记物组合、应用及其测定方法
CN105463070B (zh) * 2015-07-08 2018-12-28 上海市同仁医院 Uca1基因在制备诊断结直肠癌产品中的应用
CN105463070A (zh) * 2015-07-08 2016-04-06 上海市同仁医院 Uca1基因在制备诊断结直肠癌产品中的应用
CN108138239A (zh) * 2015-07-24 2018-06-08 高丽大学校产学协力团 用于确定衰老、确定肥胖症和诊断癌症的生物标志物和使用其的诊断试剂盒
CN108138239B (zh) * 2015-07-24 2022-08-30 高丽大学校产学协力团 用于确定衰老、确定肥胖症和诊断癌症的生物标志物和使用其的诊断试剂盒
CN108603882A (zh) * 2015-09-28 2018-09-28 雅培日本有限公司 层粘连蛋白2用于诊断肝细胞癌和胰腺癌的用途
CN108601811A (zh) * 2015-12-04 2018-09-28 得克萨斯州大学系统董事会 用于免疫治疗的slc45a2肽
WO2017113565A1 (zh) * 2015-12-29 2017-07-06 中国医学科学院肿瘤医院 基于蛋白标志物psg3辅助诊断肝癌或消化道癌症患者的试剂盒
CN106047874B (zh) * 2016-06-02 2019-01-18 吉林大学 一种靶向sall4基因的脱氧核酶分子及在乳腺癌基因治疗中的应用
CN106047874A (zh) * 2016-06-02 2016-10-26 吉林大学 一种靶向sall4基因的脱氧核酶分子及在乳腺癌基因治疗中的应用
CN108329387B (zh) * 2017-01-17 2021-07-27 复旦大学附属肿瘤医院 癌症相关的肿瘤特异转录本lin28b-tst及其用途
CN108329387A (zh) * 2017-01-17 2018-07-27 复旦大学附属肿瘤医院 癌症相关的肿瘤特异转录本lin28b-tst及其用途
WO2018218737A1 (zh) * 2017-06-01 2018-12-06 立森印迹诊断技术（无锡）有限公司 一种印记基因在膀胱肿瘤中的分级模型及其组成的系统
CN107312096A (zh) * 2017-07-17 2017-11-03 武汉博欧特生物科技有限公司 用于检测组蛋白位点三甲基化修饰的重组蛋白及其应用
CN107312096B (zh) * 2017-07-17 2019-12-20 湖北大学 用于检测组蛋白位点三甲基化修饰的重组蛋白及其应用
CN107449916A (zh) * 2017-07-27 2017-12-08 北京邦菲生物科技有限公司 肺癌和肺部结节蛋白特征谱及其构建方法与应用
CN108152496A (zh) * 2017-11-24 2018-06-12 暨南大学 Mest蛋白在制备肺癌辅助诊断和/或预后判断的试剂盒中的应用
CN107807243A (zh) * 2017-11-24 2018-03-16 暨南大学 一种食管癌的生物标志物及其应用
CN111479822A (zh) * 2017-12-13 2020-07-31 艾诺奥医药品有限公司 靶向lemd1的癌症疫苗和其用途
CN111954816A (zh) * 2018-03-08 2020-11-17 英美偌科有限公司 检测magea4的方法
CN112639132A (zh) * 2018-05-29 2021-04-09 图尔库大学 L1td1作为结肠癌的预测生物标志物
CN108796079A (zh) * 2018-06-06 2018-11-13 天津医科大学肿瘤医院 一种逆转录转座基因l1-fggy及其作为肺鳞癌标志物的用途
CN108796079B (zh) * 2018-06-06 2021-07-27 天津医科大学肿瘤医院 一种逆转录转座基因l1-fggy及其作为肺鳞癌标志物的用途
CN109082473A (zh) * 2018-10-16 2018-12-25 兰州大学 一种公牛znf280ay基因拷贝数变异的检测方法及应用
CN109371023A (zh) * 2018-12-11 2019-02-22 宁夏医科大学总医院 一种环状RNA hsa_circKIAA1199_006及其特异性扩增引物和应用
CN114127114B (zh) * 2019-04-30 2025-02-25 Absci公司 癌相关抗体组合物和使用方法
US12134655B2 (en) 2019-04-30 2024-11-05 Absci Corporation Cancer associated antibody compositions and methods of use
CN114127114A (zh) * 2019-04-30 2022-03-01 目标发现联合第二附属有限责任公司 癌相关抗体组合物和使用方法
CN110218796A (zh) * 2019-06-27 2019-09-10 江门市中心医院 用于乳腺癌骨转移诊疗的新靶标pcdhb2
CN112147324A (zh) * 2019-06-28 2020-12-29 欧蒙医学实验诊断股份公司 自身抗体的检测
CN111218509B (zh) * 2019-12-23 2023-07-04 西南医科大学附属医院 乳腺癌的新诊断标志物ppef1及其应用
CN111218509A (zh) * 2019-12-23 2020-06-02 西南医科大学附属医院 乳腺癌的新诊断标志物ppef1及其应用
CN112626210A (zh) * 2020-12-22 2021-04-09 上海市第一人民医院 诊断标志物gata4在胰腺“炎癌转化”中的应用
CN116087519B (zh) * 2021-05-17 2025-03-14 郑州大学第一附属医院 一种用于高危人群贲门腺癌早期筛查的标志物及其应用
CN116087519A (zh) * 2021-05-17 2023-05-09 郑州大学第一附属医院 一种用于高危人群贲门腺癌早期筛查的标志物及其应用
CN113504370B (zh) * 2021-06-29 2024-02-09 广州金研生物医药研究院有限公司 Mapk15蛋白在前列腺癌的恶性程度或预后程度预测中的应用
CN113504370A (zh) * 2021-06-29 2021-10-15 广州金研生物医药研究院有限公司 Mapk15蛋白在前列腺癌的恶性程度或预后程度预测中的应用
WO2023273257A1 (zh) * 2021-06-30 2023-01-05 武汉艾米森生命科技有限公司 一种结直肠癌或癌前病变的诊断或辅助诊断试剂、核酸组合、试剂盒及应用
WO2023029489A1 (zh) * 2021-09-03 2023-03-09 中山大学 一种寡核苷酸rna双链分子及其在制备治疗恶性肿瘤药物中的应用
CN115992229A (zh) * 2022-07-22 2023-04-21 中南大学湘雅三医院 一种胰腺癌预后风险评估的lncRNA标记物、模型及其应用
CN115992229B (zh) * 2022-07-22 2023-07-07 中南大学湘雅三医院 一种胰腺癌预后风险评估的lncRNA标记物、模型及其应用
CN115838804A (zh) * 2022-10-07 2023-03-24 厦门医学院 血浆外泌体lncRNAs作为靶标在急性髓系白血病诊断和疗效监测中的应用
CN115786518A (zh) * 2022-11-29 2023-03-14 广东医科大学附属医院 嗅素结构域家族蛋白4（olfm4）在结肠癌检测产品中的应用
CN116482365B (zh) * 2023-03-14 2023-10-20 南京芯原生物科技有限公司 用于检测血清抗体的蛋白组合物及其应用
CN116482365A (zh) * 2023-03-14 2023-07-25 南京芯原生物科技有限公司 用于检测血清抗体的蛋白组合物及其应用

Also Published As

Publication number Publication date
AU2012301664A1 (en) 2014-02-27
WO2013033609A2 (en) 2013-03-07
HK1199099A1 (en) 2015-06-19
US20140206574A1 (en) 2014-07-24
WO2013033609A3 (en) 2013-06-27
JP2014525584A (ja) 2014-09-29
KR20140057361A (ko) 2014-05-12
CA2844793A1 (en) 2013-03-07
EP2751570A2 (en) 2014-07-09
EP2751570A4 (en) 2015-08-12

Similar Documents

Publication Publication Date Title
CN103890587A (zh) 用于治疗和诊断癌症的方法和组合物
CN103907022A (zh) 用于治疗和诊断结直肠癌的方法和组合物
AU2012296405B2 (en) Methods and compositions for the treatment and diagnosis of breast cancer
CN103975078B (zh) 治疗和诊断膀胱癌的方法和组合物
US20160367628A1 (en) Molecular marker for cancer stem cell
JP2008546387A (ja) 癌を処置および診断するための組成物および方法
US20150018235A1 (en) Methods and Compositions for the Treatment and Diagnosis of Pancreatic Cancer
EP2723924A1 (en) Methods and compositions for the treatment and diagnosis of cancer
CN109797151A (zh) Circ-CDH1抑制剂的应用
KR102216590B1 (ko) 췌장 신경내분비종양의 진단을 위한 조성물
US20140315743A1 (en) Methods and Compositions for the Treatment and Diagnosis of Ovarian Cancer
WO2015013455A2 (en) Methods and compositions for the treatment and diagnosis of cancer
KR101612356B1 (ko) Hoxb5의 유방암 진단 및 치료 용도
WO2010050268A1 (ja) がん幹細胞分子マーカー
KR20160029053A (ko) Hoxb5의 유방암 진단 및 치료 용도
WO2018025869A1 (ja) がん患者におけるｆｓｔｌ１阻害剤による治療効果を予測するためのバイオマーカー
KR101796091B1 (ko) 카복실 말단 조절 단백질을 포함하는 두경부암 진단용 바이오 마커 조성물

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20171003

AD01 Patent right deemed abandoned